Injectafer, primarily and originally manufactured by Vifor Pharmaceuticals, has been linked to serious side effects, such as rhabdomyolysis, cardiac arrest, cardiac arrhythmia, or respiratory failure, that users and doctors were not warned about. The drug is intended to treat iron deficiency amenia by acting as an iron replacement. Patients who do not benefit from iron tablets taken orally or who have non-dialysis dependent chronic kidney disease have been prescribed Injectafer the most often.
Did you take Injectafer through a prescription and are now experiencing dangerous side effects like hypophosphatemia (HPP) or cardiovascular complications? The drug could be to blame. Call (212) 684-1880 to speak with an Injectafer lawsuit attorney from Rheingold Giuffra Ruffo & Plotkin LLP in New York. Using our extensive experience with dangerous drug claims managed on behalf of plaintiffs, we can help determine if you have a valid claim against Injectafer and what to do next if you do.
We help clients nationwide. Initial consultations are free. Get started today.
In 2013, Injectafer was first approved for sale and use in the United States. This decision was made despite the Food and Drug Administration (FDA) first rejecting the drug in 2006. The FDA cited that using Injectafer could cause dangerously low blood phosphorous levels, which can trigger hypophosphatemia. Because phosphate is an electrolyte that helps your body with energy production and nerve function, low levels can be severely problematic if not dangerous.
HPP can worsen until it causes various health conditions, including but not limited to:
A 2015 study further concluded a connection between Injectafer use and HPP. Researchers noted that 13% of all Injectafer users had been diagnosed with severe cases of hypophosphatemia. A year later, another study also reached the conclusion that Injectafer put people at a high HPP risk. Lastly, yet another study in 2019 found that Injectafer users with inflammatory bowel disease had an inordinately high-rate of HPP diagnoses, most likely connected to the drug’s main ingredient: ferric carboxymaltose (FCM).
Ferric carboxymaltose is a chemical compound in Injectafer that other iron replacements and anemia treatment medicines do not use. It is believed that FCM causes an abnormal production increase in 23 different hormones in the body. The higher levels of these hormones, the higher the risk of developing hypophosphatemia. It is not immediately clear why Injectafer’s manufacturers decided to use FCM when similar pharmaceuticals do not contain this substance.
The manufacturers of Injectafer did not attempt to warn doctors and patients about increased HPP risks when using the drug. Future investigations could also reveal that the potential side effects of FCM and prolonged Injectafer use were not properly studied before the drug was sent to the market.
Our New York Injectafer injury attorneys of Rheingold Giuffra Ruffo & Plotkin LLP are currently looking into Injectafer claims, lawsuits, and studies. If you have taken Injectafer and have been diagnosed with HPP, then we want to hear from you, too. You could have a valid claim to file, but not know it until we get a chance to review what happened to you.
Choose a legal team that has taken on international pharmaceutical companies and won. Call us at (212) 684-1880 now.